MilliporeSigma
All Photos(1)

1.50469

Supelco

Purospher® STAR RP-18 endcapped (3µm) Hibar® RT 100-4.6

suitable for HPLC

material

stainless steel column

Quality Level

Agency

suitable for USP L1

product line

Purospher®

feature

endcapped

packaging

1 ea of

extent of labeling

17% Carbon loading

parameter

400 bar pressure
65 °C max. temp.

technique(s)

HPLC: suitable
LC/MS: suitable
mass spectrometry (MS): suitable (High)

column L × I.D.

10 cm × 4.6 mm

matrix

fully porous particle

matrix active group

C18 bonding phase

particle size

3 μm

pore size

120 Å pore size

surface area

330 m2/g

operating pH range

1.5-10.5

separation technique

reversed phase
supercritical fluid (SFC)

storage temp.

no temp limit

General description

HPLC column
Purospher® STAR RP-18 endcapped is the best choice for HPLC separation of basic, neutral, metal chelating samples or indeed any other format. Its outstanding performance and stability, allows a maximum flexibility in method development. Robust methods can be developed across the entire pH spectrum from 1.5 to 10.5 enabling the use of the complete range of mobile phases.

Analysis Note

Pressure: ≤ 130 bar
Theoretical Plates (N/m) (Anthracene): ≥ 120000
Symmetry (Anthracene): 0.8 - 1.4
Capacity factor (Anthracene): 4.0 - 6.0

Legal Information

Hibar is a registered trademark of Merck KGaA, Darmstadt, Germany
Purospher is a registered trademark of Merck KGaA, Darmstadt, Germany

Certificate of Analysis

Enter Lot Number to search for Certificate of Analysis (COA).

Certificate of Quality

Enter Lot Number to search for Certificate of Quality (COQ).

Protocols

Identification, Assay and Organic Impurity Profiling Methods for Aripiprazole following the United States Pharmacopeia Monograph

Aripiprazole is an atypical antipsychotic and a partial dopamine agonist. It is primarily used in the treatment of schizophrenia, bipolar disorder, major depressive disorder, tic disorders, and irritability associated with autism. Aripiprazole was first approved by the U.S. Food and DrugAdministration in November 2002 for schizophrenia and by the European Medicines Agency in June 2004 for acute manic and mixed episodes associated with bipolar disorder.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service